Humacyte

(NASDAQ) HUMA

Current Price$1.41

Market Cap$310.83M

Since IPO (2020)-86%

5 Year-86%

1 Year-46%

1 Month+51%

Humacyte Financials at a Glance

Market Cap

$310.83M

Revenue (TTM)

$2.02M

Net Income (TTM)

-$97.59M

EPS (TTM)

-$0.57

P/E Ratio

-2.44

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Price

$1.41

Volume

110,675.609

Open

$1.39

Price

$1.41

Volume

110,675.609

Open

$1.39

Previous Close

$1.40

Daily Range

$1.39 - $1.40

52-Week Range

$0.55 - $2.93

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Price

$1.41

Volume

110,675.609

Open

$1.39

Previous Close

$1.40

Daily Range

$1.39 - $1.40

52-Week Range

$0.55 - $2.93

HUMA News

Humacyte Posts Q2 Revenue Miss

Motley Fool Markets TeamAug 11, 2025

HUMA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Humacyte

Industry

Biotechnology

Sector

Health Care

Employees

184

CEO

Laura E. Niklason, MD, PhD

Website

humacyte.com

Headquarters

Durham, NC 27713, US

HUMA Financials

Key Financial Metrics (TTM)

Gross Margin

-7%

Operating Margin

-56%

Net Income Margin

-48%

Return on Equity

-409%

Return on Capital

-1%

Return on Assets

-88%

Earnings Yield

-40.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$310.83M

Shares Outstanding

222.02M

Volume

110.68K

Avg. Volume

7.40M

Financials (TTM)

Gross Profit

-$15.01M

Operating Income

-$107.44M

EBITDA

-$100.09M

Operating Cash Flow

-$105.04M

Capital Expenditure

-$884.00K

Free Cash Flow

-$105.93M

Cash & ST Invst.

$50.50M

Total Debt

$64.85M

Humacyte Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$495.00K

-4.3%

Gross Profit

-$1.54M

-5.5%

Gross Margin

-3.12%

N/A

Market Cap

$310.83M

N/A

Market Cap/Employee

$1.43M

N/A

Employees

218

N/A

Net Income

-$17.62M

-145.0%

EBITDA

-$27.15M

-161.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

-$17.36M

-136.9%

Accounts Receivable

$434.00K

-11.1%

Inventory

$9.92M

+23.7%

Long Term Debt

$63.47M

+394.2%

Short Term Debt

$2.43M

-19.2%

Return on Assets

-88.27%

N/A

Return on Invested Capital

-1.21%

N/A

Free Cash Flow

-$25.28M

+12.3%

Operating Cash Flow

-$25.10M

+12.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NAUTNautilus Biotechnology, Inc.

NAUTNautilus Biotechnology, Inc.$2.66+2.91%

AVIRAtea Pharmaceuticals, Inc.

AVIRAtea Pharmaceuticals, Inc.$4.37+3.80%

TRDAEntrada Therapeutics, Inc.

TRDAEntrada Therapeutics, Inc.$6.72+2.13%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$6.19+1.64%

SGMTSagimet Biosciences Inc.

SGMTSagimet Biosciences Inc.$7.06+2.92%

VYGRVoyager Therapeutics, Inc.

VYGRVoyager Therapeutics, Inc.$3.67+1.94%

FHTXFoghorn Therapeutics Inc.

FHTXFoghorn Therapeutics Inc.$3.75+3.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$37.19+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$86.56-0.01%

NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF

NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF$6.42-0.15%

BBBlackBerry

BBBlackBerry$10.18-0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$36.25-0.02%

NOKNokia

NOKNokia$15.62-0.07%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$13.49-0.01%

Questions About HUMA

What is the current price of Humacyte?

Humacyte is trading at $1.40 per share.

What is the 52-week range for Humacyte?

Over the past 52 weeks, Humacyte has traded between $0.55 and $2.93.

How much debt does Humacyte have?

As of the most recent reporting period, Humacyte reported total debt of $65.90M.

How much cash does Humacyte have on hand?

Humacyte reported $48.68M in cash and cash equivalents in its most recent financial results.

What is Humacyte’s dividend yield?

Humacyte does not currently have a dividend yield.

Humacyte

Humacyte Financials at a Glance

HUMA News

Humacyte Posts Q2 Revenue Miss

HUMA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Humacyte

HUMA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Humacyte Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HUMA

What is the current price of Humacyte?

What is the 52-week range for Humacyte?

How much debt does Humacyte have?

How much cash does Humacyte have on hand?

What is Humacyte’s dividend yield?

Premium Investing Services